# BioAtla Inc. (BCAB)

Source: https://www.quantisnow.com/company/BCAB
Generated: 2026-11-10T12:03:06.454Z

- Ticker: BCAB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2020
- SEC CIK: 0001826892
- Website: bioatla.com

## About

BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.

## Latest BCAB news and filings

- 2026-10-30 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-bioatla-inc-6764344)
- 2026-10-29 21:19 UTC [SEC Form 424B3] [SEC Form 424B3 filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-bioatla-inc-6764101)
- 2026-10-27 21:28 UTC [SEC Form RW filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-rw-filed-by-bioatla-inc-6759999)
- 2026-10-20 01:42 UTC [SEC Form S-1] [SEC Form S-1 filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-bioatla-inc-6751262)
- 2026-10-20 01:33 UTC [SEC Form 8-K] [SEC Form 8-K filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-bioatla-inc-6751259)
- 2026-09-29 21:16 UTC [SEC Form 8-K] [BioAtla Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bioatla-inc-filed-sec-form-8-k-leadership-update-financial-statements-6729518)
- 2026-09-02 21:28 UTC [SEC Form 4] [Chief Medical Officer Sievers Eric covered exercise/tax liability with 134 shares, decreasing direct ownership by 1% to 11,346 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-sievers-eric-covered-exercisetax-liability-with-134-6703717)
- 2026-09-02 21:27 UTC [SEC Form 4] [Chief Executive Officer Short Jay M Phd covered exercise/tax liability with 259 shares, decreasing direct ownership by 0.50% to 52,035 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-short-jay-m-phd-covered-exercisetax-liability-6703708)
- 2026-09-02 21:26 UTC [SEC Form 4] [Chief Financial Officer Vasquez Christian covered exercise/tax liability with 71 shares, decreasing direct ownership by 0.67% to 10,476 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-vasquez-christian-covered-exercisetax-liability-with-71-6703706)
- 2026-08-28 12:01 UTC [SEC Form 8-K] [BioAtla Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/bioatla-inc-filed-sec-form-8-k-notice-of-delisting-or-6697941)
- 2026-08-13 21:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bioatla-inc-6681153)
- 2026-07-16 20:12 UTC [SEC Form 8-K] [BioAtla Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/bioatla-inc-filed-sec-form-8-k-submission-of-matters-to-6639736)
- 2026-06-05 20:30 UTC [SEC Form 4] [Chief Financial Officer Vasquez Christian covered exercise/tax liability with 257 shares, decreasing direct ownership by 2% to 10,347 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-vasquez-christian-covered-exercisetax-liability-with-257-6591527)
- 2026-06-05 20:30 UTC [SEC Form 4] [Chief Executive Officer Short Jay M Phd covered exercise/tax liability with 898 shares, decreasing direct ownership by 2% to 52,294 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-short-jay-m-phd-covered-exercisetax-liability-6591507)
- 2026-06-05 20:30 UTC [SEC Form 4] [Chief Medical Officer Sievers Eric covered exercise/tax liability with 494 shares, decreasing direct ownership by 1% to 11,840 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-sievers-eric-covered-exercisetax-liability-with-494-6591502)
- 2026-06-03 20:08 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-bioatla-inc-6586774)
- 2026-06-03 20:07 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-bioatla-inc-6586747)
- 2026-05-18 10:45 UTC [Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202](https://www.quantisnow.com/insight/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-6558997)
- 2026-05-15 20:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bioatla-inc-6557172)
- 2026-04-29 20:05 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by BioAtla Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-bioatla-inc-6521137)
- 2026-04-02 20:05 UTC [SEC Form 8-K] [BioAtla Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bioatla-inc-filed-sec-form-8-k-other-events-financial-statements-6484432)
- 2026-03-31 20:50 UTC [SEC Form S-8] [SEC Form S-8 filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-bioatla-inc-6479757)
- 2026-03-31 20:05 UTC [SEC Form 8-K] [BioAtla Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bioatla-inc-filed-sec-form-8-k-results-of-operations-and-6479022)
- 2026-03-31 20:05 UTC [SEC Form 10-K] [SEC Form 10-K filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-bioatla-inc-6478999)
- 2026-03-31 20:06 UTC [BioAtla Announces Share Consolidation](https://www.quantisnow.com/insight/bioatla-announces-share-consolidation-6478984)
- 2026-03-31 20:05 UTC [Earnings] [BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights](https://www.quantisnow.com/insight/bioatla-reports-fourth-quarter-and-full-year-2025-financial-results-6478941)
- 2026-03-23 20:04 UTC [SEC Form 8-K] [BioAtla Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/bioatla-inc-filed-sec-form-8-k-leadership-update-submission-of-6464940)
- 2026-03-12 20:08 UTC [SEC Form 4] [Chief Medical Officer Sievers Eric was granted 240,000 shares, increasing direct ownership by 67% to 598,705 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-sievers-eric-was-granted-240000-shares-increasing-6444476)
- 2026-03-12 20:07 UTC [SEC Form 4] [Chief Executive Officer Short Jay M Phd was granted 430,000 shares, increasing direct ownership by 19% to 2,659,603 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-short-jay-m-phd-was-granted-430000-6444470)
- 2026-03-12 20:07 UTC [SEC Form 4] [Chief Financial Officer Vasquez Christian was granted 240,000 shares, increasing direct ownership by 83% to 530,196 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-vasquez-christian-was-granted-240000-shares-increasing-6444458)
- 2026-03-02 23:14 UTC [SEC Form 4] [Chief Executive Officer Short Jay M Phd covered exercise/tax liability with 7,728 shares, decreasing direct ownership by 0.35% to 2,229,603 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-short-jay-m-phd-covered-exercisetax-liability-6423112)
- 2026-03-02 23:14 UTC [SEC Form 4] [Chief Financial Officer Vasquez Christian covered exercise/tax liability with 1,802 shares, decreasing direct ownership by 0.62% to 290,196 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-vasquez-christian-covered-exercisetax-liability-with-1802-6423111)
- 2026-03-02 23:14 UTC [SEC Form 4] [Former Chief Financial Officer Waldron Richard A covered exercise/tax liability with 2,729 shares, decreasing direct ownership by 0.79% to 343,421 units (SEC Form 4)](https://www.quantisnow.com/insight/former-chief-financial-officer-waldron-richard-a-covered-exercisetax-liability-6423108)
- 2026-03-02 23:13 UTC [SEC Form 4] [Chief Medical Officer Sievers Eric covered exercise/tax liability with 3,140 shares, decreasing direct ownership by 0.87% to 358,705 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-sievers-eric-covered-exercisetax-liability-with-3140-6423107)
- 2026-03-02 12:42 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-bioatla-inc-6420773)
- 2026-03-02 12:41 UTC [SEC Form 8-K] [BioAtla Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bioatla-inc-filed-sec-form-8-k-results-of-operations-and-6420771)
- 2026-03-02 12:30 UTC [BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets](https://www.quantisnow.com/insight/bioatla-announces-formal-process-to-evaluate-strategic-options-to-monetize-6420745)
- 2026-02-11 21:05 UTC [SEC Form DEFM14A] [SEC Form DEFM14A filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-defm14a-filed-by-bioatla-inc-6386539)
- 2026-02-09 11:01 UTC [SEC Form 8-K] [SEC Form 8-K filed by BioAtla Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-bioatla-inc-6380683)
- 2026-02-06 22:02 UTC [SEC Form 8-K] [BioAtla Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure](https://www.quantisnow.com/insight/bioatla-inc-filed-sec-form-8-k-notice-of-delisting-or-6380240)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/BCAB
- Earnings history: https://www.quantisnow.com/earnings/BCAB
- Dividend history: https://www.quantisnow.com/dividends/BCAB
- Insider transactions: https://www.quantisnow.com/insiders/BCAB
- Options chain: https://www.quantisnow.com/options/BCAB
- SEC 8-K filings only: https://www.quantisnow.com/company/BCAB/8-k
- RSS and alerts for BCAB: https://www.quantisnow.com/docs/rss-feeds.md